Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Libai CHEN"'
Autor:
Huiyan Yang, Jingyu Gao, Yongsheng Ruan, Zhaokun Chen, Ruihan Fang, Lei Zhang, Zhibiao Wang, Tiantian Yi, Qian Zhang, Yang Luo, Libai Chen, Xuedong Wu
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: Chemotherapy-induced thrombocytopenia (CIT) commonly exacerbates the difficulty of cancer treatment, increasing bleeding risks and potentially reducing chemotherapy dosage, ultimately impacting its efficacy. However, there are limited stu
Externí odkaz:
https://doaj.org/article/9e96749e3c614dec997a3c0cdfa70250
Autor:
Yongsheng Ruan, Libai Chen, Tingting Luo, Danfeng Xie, Wei Cao, Xuan Liu, Qiujun Liu, Yuhua Xiao, Cuiling Wu, Jianyun Wen, Juan Li, Jiangnan Meng, Xuedong Wu, Xiaoqin Feng
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 8, Pp 2071-2086 (2023)
Abstract Introduction Since hematopoietic stem cell transplant (HSCT) is an important therapy for malignant and non-malignant pediatric diseases, improving transplant-related mortality remains a challenge. Currently, rituximab, a monoclonal antibody
Externí odkaz:
https://doaj.org/article/430a2f50f5da4ae0b462ff8d5e77997c
Autor:
Jianyun WEN, Libai CHEN, Jing DU, Xiaoxiao XU, Yuelin HE, Yongsheng RUAN, Xiu LI, Juan LI, Xuedong WU
Publikováno v:
Zhongguo shuxue zazhi, Vol 36, Iss 6, Pp 500-504 (2023)
Objective To evaluate the safety and efficacy of the collection of peripheral blood stem cells (PBSCs) in pediatric patients with thalassemia major (TM) weighing 20 kg or less. Methods PBSCs collection data of 170 pediatric patients with TM weighing
Externí odkaz:
https://doaj.org/article/8daf46a1c51843c09479c449855d90cd
Autor:
Jianyun Wen, Xiaodong Wang, Libai Chen, Yuelin He, Xiaoqin Feng, Chunfu Li, Yongshen Ruan, Sixi Liu, Xuedong Wu
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 310-317 (2022)
Background Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment for thalassaemia major (TM). Cord blood (CB) from a sibling has different characteristics from marrow and has potential advantages and
Externí odkaz:
https://doaj.org/article/98e6594769f14e3a9ccab826f116de9e
Autor:
Yongsheng Ruan, Tingting Luo, Qiujun Liu, Xuan Liu, Libai Chen, Jianyun Wen, Yuhua Xiao, Danfeng Xie, Yuelin He, Xuedong Wu, Xiaoqin Feng
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Cytomegalovirus (CMV) infection remains a critical cause of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), despite improvement by pre-emptive antivirus treatment. CMV-specific cytotoxic T lymphocytes (CMV-CTL) are uni
Externí odkaz:
https://doaj.org/article/b9672d22fad849258f086362f63a4e1c
Autor:
Yongsheng Ruan, Libai Chen, Danfeng Xie, Tingting Luo, Yiqi Xu, Tao Ye, Xiaona Chen, Xiaoqin Feng, Xuedong Wu
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Chemotherapy is a critical treatment for endocrine-related cancers; however, chemoresistance and disease recurrence remain a challenge. The interplay between cancer cells and the tumor microenvironment via cell adhesion molecules (CAMs) promotes drug
Externí odkaz:
https://doaj.org/article/05341c4055f14d5a9781caf260c93e30
Autor:
Jieming, Yu, Tiantian, Yi, Guanchuan, Lin, Jianyun, Wen, Libai, Chen, Jiaqi, Chen, Xuedong, Wu
Publikováno v:
Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 40(2)
OBJECTIVE: To assess the prognostic value of minimal residual disease on 19th day of induction chemotherapy (D19 MRD) and the risk factors of D19 MRD ≥ 1% in children with acute lymphoblastic leukemia (ALL) treated following the Chinese Children's
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::07b09a6530ff62d9d8343d775ee71abe
https://pubmed.ncbi.nlm.nih.gov/32376526
https://pubmed.ncbi.nlm.nih.gov/32376526
Autor:
Xiaoqin Feng, Libai Chen, Jianyun Wen, Yongsheng Ruan, Yue-lin He, Chunfu Li, Xuan Liu, Fuyu Pei, Xuedong Wu, Qareen Haque
Publikováno v:
Acta Haematologica. 140:20-29
Background: Hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for thalassemia majorTM. Graft rejection (GR) and graft-versus-host disease (GVHD) are the primary obstacles to a successful outcome. Methods: We cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e72eaff46e1a0baa70bf524374a20c9
https://doi.org/10.1159/000490407
https://doi.org/10.1159/000490407
Autor:
Xiaodong Wang, Jianyun Wen, Xuan Liu, Wing Leung, Yuqiong Ren, Li Yu, Xiaoqin Feng, Yuelin He, Yuhua Xiao, Sixi Liu, Xiaoling Wang, Xiaoting Liu, Libai Chen, Chunfu Li, Yongsheng Ruan
Publikováno v:
Blood. 138:2875-2875
Background: For patients without HLA matched donor, Haploid stem cell transplantation with PTCY method has relatively higher risk of relapse and graft-versus-host disease (GVHD). Umbilical cord blood (UCB) is readily available and has helped expand t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edcc1b1382fe7571bb22b73dcf270cd0
https://doi.org/10.1182/blood-2021-150888
https://doi.org/10.1182/blood-2021-150888
Autor:
Chunfu Li, Xiaoxiao Xu, Xuedong Wu, Xuan Liu, Yuelin He, Libai Chen, Xiaoqin Feng, Jianyun Wen, Fuyu Pei
Publikováno v:
Blood. 134:801-801
Background:Hematopoietic stem cell transplantation(HSCT) is currently the only treatment shown to provide an effective, definitive cure for β-thalassemia major (TM). All over the world a major constraint is the lack of access to this therapy related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f79910ff3f78ec6eed63498e61af155
https://doi.org/10.1182/blood-2019-130038
https://doi.org/10.1182/blood-2019-130038